Swathi Raju Nallapa, MD
Internal Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
- Since medical school
- 8 years
- Graduated 2018
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 058123 · 059546 · 757662 · El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nallapa’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A167018 · Current
Licensed to practise in California · since 2019 · expires 2027-12-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$109,742
Medicare paid this office $109,742 for 352 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 187 | $29,339 | $157 |
| Return visit (30+ min) | 210 | $28,466 | $104 |
| Long return visit (40+ min) | 134 | $25,772 | $152 |
| Short return visit (20+ min) | 120 | $9,438 | $69 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 13 | $3,760 | $289 |
See all 10 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 187 | $29,339 | $157 |
| Return visit (30+ min) | 210 | $28,466 | $104 |
| Long return visit (40+ min) | 134 | $25,772 | $152 |
| Short return visit (20+ min) | 120 | $9,438 | $69 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 13 | $3,760 | $289 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 152 | $3,547 | $14 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 18 | $1,164 | $53 |
| Influenza vaccine, inactivated | 11 | $900 | $82 |
| Administration of pneumococcal vaccine | 15 | $544 | $36 |
| Administration of influenza virus vaccine | 11 | $430 | $39 |
Who their Medicare patients are
352 Original Medicare patients in 2024. Average age 78 · Women 67% · Also on Medicaid 4% · Health risk score 0.86. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 59% · Coronary heart disease 17% · Cancer 17% · Chronic kidney disease 16% · Atrial fibrillation 16% · Depression 16% · Diabetes 12% · Dementia 8% · Heart failure 6% · COPD 5% · Stroke 5%.
The office billed $304,567, Medicare allowed $141,754 and paid $109,742; for 1,161 services of 32 kinds; $6,649 of it was for drugs given in the office and $103,093 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 352 | 1,161 | 78 | 0.86 | $304,567 | $109,742 |
| 2023 | 418 | 1,083 | 78 | 0.83 | $311,496 | $125,702 |
| 2022 | 363 | 676 | 78 | 0.87 | $168,532 | $66,379 |
| 2021 | 82 | 129 | 77 | 0.73 | $22,912 | $10,156 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 227 | $35,389 | $156 |
| Return visit (30+ min) | 236 | $32,193 | $108 |
| Long return visit (40+ min) | 146 | $31,752 | $160 |
| Short return visit (20+ min) | 133 | $11,439 | $74 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 43 | $3,254 | $76 |
| Administration of influenza virus vaccine | 44 | $1,626 | $37 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 14 | $926 | $49 |
| Administration of pneumococcal vaccine | 13 | $446 | $34 |
2022: 8 services
| Return visit (30+ min) | 161 | $21,543 | $110 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 108 | $16,805 | $156 |
| Short return visit (20+ min) | 162 | $14,245 | $73 |
| Long return visit (40+ min) | 37 | $5,633 | $144 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 20 | $1,405 | $70 |
| Administration of influenza virus vaccine | 21 | $782 | $37 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $732 | $67 |
| Short return visit | 17 | $557 | $33 |
2021: 4 services
| Short return visit (20+ min) | 59 | $5,730 | $88 |
| Influenza vaccine split virus, preservative free | 13 | $848 | $65 |
| Short return visit | 11 | $560 | $51 |
| Administration of influenza virus vaccine | 14 | $303 | $22 |
Drugs they prescribed that Part D paid
$222,278
Pharmacies billed $222,278 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (31 of 2,987) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
2,686 generic and fewer than 11 brand-name prescriptions · $222,278 in drug cost · 49 antibiotic prescriptions to 36 people · 11 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 40 | $47,817 | $1,195 |
| Ozempic | 31 | $39,642 | $1,279 |
| Estring | 11 | $5,711 | $519 |
| Atorvastatin | 315 | $3,355 | $11 |
| Estradiol | 23 | $3,199 | $139 |
See all 59 drugs
| Eliquis | 40 | $47,817 | $1,195 |
| Ozempic | 31 | $39,642 | $1,279 |
| Estring | 11 | $5,711 | $519 |
| Atorvastatin | 315 | $3,355 | $11 |
| Estradiol | 23 | $3,199 | $139 |
| Levothyroxine | 159 | $2,061 | $13 |
| Synthroid | 15 | $1,751 | $117 |
| Amlodipine Besylate | 218 | $1,728 | $8 |
| Tamsulosin | 54 | $1,256 | $23 |
| Metoprolol | 68 | $1,188 | $17 |
| Rosuvastatin | 87 | $1,094 | $13 |
| Lidocaine | 12 | $1,062 | $89 |
| Lisinopril | 124 | $1,023 | $8 |
| Valacyclovir | 15 | $953 | $64 |
| Trazodone | 68 | $937 | $14 |
| Gabapentin | 83 | $865 | $10 |
| Alendronate | 63 | $859 | $14 |
| Simvastatin | 59 | $784 | $13 |
| Losartan | 100 | $735 | $7 |
| Metformin Hcl Er | 45 | $713 | $16 |
| Duloxetine | 14 | $657 | $47 |
| Pantoprazole | 20 | $615 | $31 |
| Hydrocodone-Acetaminophen | 13 | $604 | $46 |
| Escitalopram | 29 | $581 | $20 |
| Irbesartan | 25 | $560 | $22 |
| Albuterol Sulfate Hfa | 15 | $486 | $32 |
| Venlafaxine Hcl Er | 17 | $480 | $28 |
| Allopurinol | 39 | $467 | $12 |
| Valsartan | 27 | $452 | $17 |
| Pravastatin | 32 | $439 | $14 |
| Omeprazole | 41 | $426 | $10 |
| Finasteride | 23 | $423 | $18 |
| Fluoxetine | 20 | $406 | $20 |
| Sertraline | 35 | $390 | $11 |
| Fluticasone Propionate | 13 | $362 | $28 |
| Metformin | 30 | $349 | $12 |
| Bupropion Xl | 11 | $348 | $32 |
| Hydrochlorothiazide | 39 | $344 | $9 |
| Buspirone | 16 | $340 | $21 |
| Ondansetron Odt | 17 | $308 | $18 |
| Spironolactone | 32 | $306 | $10 |
| Lorazepam | 55 | $267 | $5 |
| Chlorthalidone | 15 | $240 | $16 |
| Famotidine | 12 | $221 | $18 |
| Ipratropium | 13 | $216 | $17 |
| Zolpidem | 37 | $200 | $5 |
| Carvedilol | 30 | $174 | $6 |
| Diltiazem 24hr Er (Cd) | 11 | $154 | $14 |
| Citalopram Hbr | 15 | $150 | $10 |
| Mirtazapine | 17 | $144 | $8 |
| Triamterene-Hydrochlorothiazid | 12 | $131 | $11 |
| Lovastatin | 17 | $118 | $7 |
| Cephalexin | 20 | $110 | $5 |
| Potassium Chloride | 12 | $103 | $9 |
| Glipizide | 16 | $74 | $5 |
| Furosemide | 11 | $61 | $6 |
| Clonazepam | 17 | $55 | $3 |
| Atenolol | 12 | $26 | $2 |
| Paxlovid | 11 | $0 | $0 |
Year by year
| 2024 | 2,987 | 337 | 1% (31) | None | $222,278 |
| 2023 | 2,359 | 370 | 2% (45) | 9% | $161,569 |
| 2022 | 938 | 236 | 3% (28) | None | $54,306 |
| 2021 | 302 | 84 | 4% (13) | None | $16,487 |
| 2020 | 300 | 48 | 0% (0) | None | $19,250 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 56 drugs
| Eliquis | 30 | $40,064 | $1,335 |
| Xarelto | 11 | $8,525 | $775 |
| Premarin | 15 | $6,021 | $401 |
| Atorvastatin | 200 | $2,540 | $13 |
| Estradiol | 16 | $1,994 | $125 |
| Tamsulosin | 51 | $1,956 | $38 |
| Amlodipine Besylate | 172 | $1,770 | $10 |
| Levothyroxine | 107 | $1,732 | $16 |
| Telmisartan | 14 | $1,571 | $112 |
| Trazodone | 78 | $1,033 | $13 |
| Losartan | 76 | $991 | $13 |
| Duloxetine | 21 | $963 | $46 |
| Venlafaxine Hcl Er | 19 | $902 | $47 |
| Gabapentin | 62 | $871 | $14 |
| Lisinopril | 71 | $863 | $12 |
| Metoprolol | 39 | $840 | $22 |
| Omeprazole | 50 | $752 | $15 |
| Valacyclovir | 19 | $699 | $37 |
| Albuterol Sulfate Hfa | 24 | $685 | $29 |
| Rosuvastatin | 50 | $670 | $13 |
| Metformin Hcl Er | 28 | $667 | $24 |
| Fluticasone Propionate | 24 | $649 | $27 |
| Alendronate | 36 | $608 | $17 |
| Azelastine | 11 | $600 | $55 |
| Pravastatin | 27 | $587 | $22 |
| Felodipine Er | 11 | $583 | $53 |
| Hydrocodone-Acetaminophen | 26 | $572 | $22 |
| Valsartan | 12 | $543 | $45 |
| Ipratropium | 18 | $536 | $30 |
| Fluoxetine | 20 | $527 | $26 |
| Pantoprazole | 16 | $475 | $30 |
| Allopurinol | 35 | $464 | $13 |
| Simvastatin | 36 | $415 | $12 |
| Metformin | 32 | $391 | $12 |
| Lorazepam | 62 | $363 | $6 |
| Lisinopril-Hydrochlorothiazide | 17 | $320 | $19 |
| Hydrochlorothiazide | 33 | $316 | $10 |
| Finasteride | 21 | $313 | $15 |
| Irbesartan | 12 | $260 | $22 |
| Chlorthalidone | 14 | $240 | $17 |
| Citalopram Hbr | 14 | $230 | $16 |
| Sertraline | 14 | $218 | $16 |
| Mirtazapine | 18 | $208 | $12 |
| Paxlovid (Eua) | 19 | $201 | $11 |
| Doxazosin Mesylate | 13 | $177 | $14 |
| Nitrofurantoin Mono-Macro | 12 | $174 | $15 |
| Carvedilol | 20 | $173 | $9 |
| Atenolol | 16 | $149 | $9 |
| Zolpidem | 34 | $145 | $4 |
| Escitalopram | 14 | $125 | $9 |
| Spironolactone | 12 | $124 | $10 |
| Furosemide | 18 | $110 | $6 |
| Lovastatin | 16 | $93 | $6 |
| Glipizide | 16 | $53 | $3 |
| Clonazepam | 16 | $50 | $3 |
| Sildenafil Citrate | 11 | $36 | $3 |
2022: 26 drugs
| Eliquis | 17 | $12,704 | $747 |
| Levothyroxine | 31 | $801 | $26 |
| Tamsulosin | 27 | $758 | $28 |
| Losartan | 29 | $664 | $23 |
| Lidocaine | 13 | $612 | $47 |
| Amlodipine Besylate | 68 | $547 | $8 |
| Atorvastatin | 70 | $464 | $7 |
| Gabapentin | 24 | $409 | $17 |
| Metoprolol | 17 | $387 | $23 |
| Fluticasone Propionate | 18 | $318 | $18 |
| Allopurinol | 19 | $281 | $15 |
| Zolpidem | 33 | $256 | $8 |
| Pravastatin | 13 | $246 | $19 |
| Metformin | 18 | $233 | $13 |
| Hydrochlorothiazide | 22 | $222 | $10 |
| Rosuvastatin | 13 | $213 | $16 |
| Simvastatin | 12 | $212 | $18 |
| Omeprazole | 18 | $207 | $11 |
| Carvedilol | 12 | $141 | $12 |
| Lisinopril | 17 | $106 | $6 |
| Cephalexin | 14 | $104 | $7 |
| Trazodone | 11 | $103 | $9 |
| Furosemide | 12 | $92 | $8 |
| Tramadol | 18 | $80 | $4 |
| Lorazepam | 17 | $78 | $5 |
| Clonazepam | 12 | $43 | $4 |
2021: 7 drugs
| Atorvastatin | 41 | $925 | $23 |
| Diclofenac | 12 | $569 | $47 |
| Levothyroxine | 14 | $335 | $24 |
| Omeprazole | 17 | $292 | $17 |
| Gabapentin | 16 | $219 | $14 |
| Amlodipine Besylate | 19 | $196 | $10 |
| Benazepril | 17 | $123 | $7 |
2020: 9 drugs
| Novolin 70-30 | 11 | $3,415 | $310 |
| Levothyroxine | 20 | $391 | $20 |
| Diclofenac | 14 | $388 | $28 |
| Atorvastatin | 30 | $342 | $11 |
| Gabapentin | 16 | $222 | $14 |
| Omeprazole | 12 | $201 | $17 |
| Benazepril | 13 | $128 | $10 |
| Metformin | 16 | $121 | $8 |
| Amlodipine Besylate | 22 | $120 | $5 |
Money from drug and device companies
$25 in 2021
A payment is not proof that care is biased.
| Amgen | Xgeva | $25 | 1 payment
|
See the published payment
| Amgen | Meals · 2021-01-25 | Xgeva | $25 |
Professional record
- NPI
- 1780188847
- Licence
- CA A167018California A167018: Current · expires 2027-12-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2018-03-22
- NPI last updated
- 2021-09-03
- NPI record certified
- 2021-09-03
This is when the NPI record was last certified, not a medical board exam.